Implementation of the Helsinki Model at West Tallinn Central Hospital

Medicina (Kaunas). 2022 Aug 29;58(9):1173. doi: 10.3390/medicina58091173.

Abstract

Ischemic stroke is defined as neurological deficit caused by brain infarction. The intravenous tissue plasminogen activator, alteplase, is an effective treatment. However, efficacy of this method is time dependent. An important step in improving outcome and increasing the number of patients receiving alteplase is the shortening of waiting times at the hospital, the so-called door-to-needle time (DNT). The comprehensive Helsinki model was proposed in 2012, which enabled the shortening of the DNT to less than 20 min. Background and Objectives: The aim of this study was to analyze the transferability of the suggested model to the West Tallinn Central Hospital (WTCH). Materials and Methods: Since the first thrombolysis in 2005, all patients are registered in the WTCH thrombolysis registry. Several steps following the Helsinki model have been implemented over the years. Results: The results demonstrate that the number and also the percent of thrombolysed stroke patients increased during the years, from a few thrombolysis annually, to 260 in 2021. The mean DNT dropped significantly to 33 min after the implementation of several steps, from the emergency medical services (EMS) prenotification with a phone call to the neurologists, to the setting-up of a thrombolysis team based in the stroke unit. Also, the immediate start of treatment using a computed tomography table was introduced. Conclusions: In conclusion, several implemented steps enabled the shortening of the DNT from 30 to 25.2 min. Short DNTs were achieved and maintained only with EMS prenotification.

Keywords: door-to-needle time; outcome; pre-hospital care; quality of care; service provision; stroke; thrombolysis.

MeSH terms

  • Child
  • Emergency Service, Hospital
  • Fibrinolytic Agents / therapeutic use
  • Hospitals
  • Humans
  • Stroke* / drug therapy
  • Thrombolytic Therapy / methods
  • Time Factors
  • Tissue Plasminogen Activator* / therapeutic use
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator

Grants and funding

The author(s) received financial support the publication of this article from West-Tallinn Central Hospital and Tallinn Technical University (TalTech).